CoChat
Sign Up
Cited by 35

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery

Matha, Kevin, Lollo, Giovanna, Taurino, Giuseppe, Respaud, Renaud, Marigo, Ilaria, Shariati, Molood, Bussolati, Ovidio, Vermeulen, An, Remaut, Katrien, Benoit, Jean-Pierre·2020·European Journal of Pharmaceutics and Biopharmaceutics
DOI 10.1016/j.ejpb.2020.02.008
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejpb.2020.02.008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 52

  1. Oberoi, 2013, Nanocarriers for delivery of platinum anticancer drugs, Adv. Drug Deliv. Rev., 65, 1667, 10.1016/j.addr.2013.09.014 · DOI
  2. Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat. Rev. Cancer., 7, 573, 10.1038/nrc2167 · DOI
  3. Wiltshaw, 1979, Cisplatin in the Treatment of Cancer, Platinum. Met. Rev., 23, 90, 10.1595/003214079X2339098 · DOI
  4. Raymond, 1998, Oxaliplatin: A review of preclinical and clinical studies, Ann. Onc., 9, 1053, 10.1023/A:1008213732429 · DOI
  5. Bruno, 2017, A subset of platinum-containing chemotherapeutic agents kill cells by inducing ribosome biogenesis stress rather than by engaging a DNA damage response Peter, Nat Med., 23, 461, 10.1038/nm.4291 · DOI
  6. Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356 · DOI
  7. Zhao, 2016, Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy, Biomaterials, 102, 187, 10.1016/j.biomaterials.2016.06.032 · DOI
  8. McWhinney, 2009, Platinum neurotoxicity pharmacogenetics, Mol. Cancer Ther., 8, 10, 10.1158/1535-7163.MCT-08-0840 · DOI
  9. Phan, 2009, Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis, NDT Plus., 2, 254
  10. Duvic, 2005, Renal toxicity of Oxaliplatin, Nephrol. Dial. Transplant., 20, 1275, 10.1093/ndt/gfh826 · DOI
  11. Mochida, 2017, Polymeric micelles for targeted tumor therapy of platinum anticancer drugs, Expert Opin. Drug Deliv., 17425247, 1307338
  12. Oberoi, 2012, Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles, Chemother. Res. Pract., 1
  13. Hang, 2016, Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials, Biochem. Compd., 4, 1
  14. Murakami, 2011, Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting, Sci. Transl. Med., 3, 64ra2, 10.1126/scitranslmed.3001385 · DOI
  15. Vivek, 2014, Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a “smart” drug delivery system to breast cancer cell therapy, Int. J. Biol. Macromol., 65, 289, 10.1016/j.ijbiomac.2014.01.054 · DOI
  16. Rice, 2006, Preclinical efficacy and pharmacokinetics of AP5346, A novel diaminocyclohexane-platinum tumor-targeting drug delivery system, Clin. Cancer Res., 12, 2248, 10.1158/1078-0432.CCR-05-2169 · DOI
  17. Sood, 2006, Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent, Bioconjug. Chem., 17, 1270, 10.1021/bc0600517 · DOI
  18. Cabral, 2011, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size, Nat. Nanotechnol., 6, 815, 10.1038/nnano.2011.166 · DOI · Paper page
  19. Lollo, 2018, Drug delivery system, European Patent Office, 854
  20. Oyarzun-Ampuero, 2011, A new drug nanocarrier consisting of polyarginine and hyaluronic acid, Eur. J. Pharm. Biopharm., 79, 54, 10.1016/j.ejpb.2011.04.008 · DOI
  21. Kogan, 2007, Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications, Biotechnol. Lett., 29, 17, 10.1007/s10529-006-9219-z · DOI
  22. Becker, 2009, Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate, Int. J. Toxicol., 28, 5, 10.1177/1091581809337738 · DOI
  23. Salwowska, 2016, Physiochemical properties and application of hyaluronic acid: a systematic review, J. Cosmet. Dermatol., 15, 520, 10.1111/jocd.12237 · DOI
  24. Ganesh, 2013, Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors, Biomaterials, 34, 3489, 10.1016/j.biomaterials.2013.01.077 · DOI
  25. Ganesh, 2013, In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles, J. Control. Release, 172, 699, 10.1016/j.jconrel.2013.10.016 · DOI
  26. Lollo, 2017, Polyarginine nanocapsules as a potential oral peptide delivery carrier, J. Pharm. Sci., 106, 611, 10.1016/j.xphs.2016.09.029 · DOI
  27. Carton, 2019, Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery, Int. J. Pharm., 568, 10.1016/j.ijpharm.2019.118526 · DOI
  28. Dakwar, 2014, Colloidal stability of nano-sized particles in the peritoneal fluid: towards optimizing drug delivery systems for intraperitoneal therapy, Acta Biomater., 10, 2965, 10.1016/j.actbio.2014.03.012 · DOI
  29. Braeckmans, 2010, Sizing nanomatter in biological fluids by fluorescence single particle tracking, Nano Lett., 10, 4435, 10.1021/nl103264u · DOI
  30. Weyland, 2013, Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells, Int. J. Pharm., 454, 756, 10.1016/j.ijpharm.2013.06.013 · DOI
  31. Lollo, 2015, Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma, Int. J. Pharm., 495, 972, 10.1016/j.ijpharm.2015.09.062 · DOI
  32. Lehner, 2011, Methodological and preclinical evaluation of an HMGB1 immunoassay, Anticancer Res., 31, 1989
  33. Marmiroli, 2017, Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights, PLoS One, 12, 1, 10.1371/journal.pone.0186250 · DOI
  34. Basakran, 2015, CD44 as a potential diagnostic tumor marker, Saudi Med. J., 36, 273, 10.15537/smj.2015.3.9622 · DOI
  35. Song, 2019, Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells, Mol. Carcinog., 58, 321, 10.1002/mc.22930 · DOI
  36. Cisterna, 2016, Targeted nanoparticles for colorectal cancer, Nanomedicine, 11, 2443, 10.2217/nnm-2016-0194 · DOI
  37. Vilar, 2012, Polymers and drug delivery systems, Curr. Drug Deliv., 9, 367, 10.2174/156720112801323053 · DOI
  38. Singh, 2009, Nanoparticle-based targeted drug delivery, Exp. Mol. Pathol., 86, 215, 10.1016/j.yexmp.2008.12.004 · DOI
  39. Moghimi, 2012, Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective, Annu. Rev. Pharmacol. Toxicol., 52, 481, 10.1146/annurev-pharmtox-010611-134623 · DOI
  40. Atkinson, 2018, Polymer therapeutics: Biomarkers and new approaches for personalized cancer treatment, J. Pers. Med., 8, 10.3390/jpm8010006 · DOI
  41. Poveda, 2007, Update in the management of ovarian and cervical carcinoma, Clin. Transl. Oncol., 9, 443, 10.1007/s12094-007-0083-7 · DOI
  42. Creixell, 2012, Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance, Nano Today., 7, 367, 10.1016/j.nantod.2012.06.013 · DOI
  43. Tsai, 2018, DACHPt-loaded nanoparticles self-assembled from biodegradable dendritic copolymer polyglutamic acid-b-D-α-tocopheryl polyethylene glycol 1000 succinate for multidrug resistant lung cancer therapy, Front. Pharmacol., 9, 1, 10.3389/fphar.2018.00119 · DOI
  44. Liu, 2017, DACHPt-loaded unimolecular micelles based on hydrophilic dendritic block copolymers for enhanced therapy of lung cancer, ACS Appl. Mater. Interfaces., 9, 112, 10.1021/acsami.6b11917 · DOI
  45. Toole, 1990, Hyaluronan and its binding proteins, the hyaladherins, Curr. Opin. Cell Biol., 2, 839, 10.1016/0955-0674(90)90081-O · DOI
  46. Spadea, 2019, Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44, Mol. Pharm., 16, 2481, 10.1021/acs.molpharmaceut.9b00083 · DOI
  47. Dalla Pozza, 2013, Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity, Biochim. Biophys. Acta, 5, 1396, 10.1016/j.bbamem.2013.01.020 · DOI
  48. Garg, 2017, Trial watch: immunogenic cell death induction by anticancer chemotherapeutics, Oncoimmunology., 6, e1386829, 10.1080/2162402X.2017.1386829 · DOI
  49. Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu. Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008 · DOI · Paper page
  50. Garg, 2015, Immunogenic cell death, Int. J. Dev. Biol., 59, 131, 10.1387/ijdb.150061pa · DOI
  51. Graham, 2000, Clinical pharmacokinetics of oxaliplatin : a critical review clinical, Clin. Cancer Res., 18, 1205
  52. Li, 2008, Pharmacokinetics and biodistribution of nanoparticles, Mol. Pharm., 5, 496, 10.1021/mp800049w · DOI

Cited by

Sorted by citations

See all 35

Metadata

Authors
Matha, K., Lollo, G., Taurino, G., Respaud, R., Marigo, I., Shariati, M., Bussolati, O., Vermeulen, A., Remaut, K., & Benoit, J.-P.
Venue
European Journal of Pharmaceutics and Biopharmaceutics
Publisher
Elsevier BV
Published
2020-05
Volume
150
Pages
1-13
ISSN
0939-6411
DOI
10.1016/j.ejpb.2020.02.008
Cited by
35
References
3
Language
en
Licence
Funders
Agence Nationale de la Recherche

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review